Last 12 months
Inside the activity.
9 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 4 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2022 Filed Feb 25, 2022 18:50 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
Exercise / conversionCommon Shares | 56,125 | $2.70 | $151,537.50 |
DisclosureSEC source: 0001209191-22-013012 · doc4.xml · nonDerivative · entry 1 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:00 UTC |
Booth AndrewChief Financial Officer
|
Exercise / conversionShare Options (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001209191-21-069084 · doc4.xml · derivative · entry 3 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,384,820 Underlying: Common Shares · 500,000 shares Expires 2029-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:00 UTC |
Booth AndrewChief Financial Officer
|
Exercise / conversionCommon Shares | 500,000 | $0.32 | $160,000.00 |
DisclosureSEC source: 0001209191-21-069084 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Feb 3, 2022 23:54 UTC |
Booth AndrewChief Financial Officer
|
GiftCommon Shares | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006960 · doc5.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,500 F1 · shares: This transaction represents a charitable donation of 500,000 common shares the reporting person donated on December 10, 2021. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 22:49 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionShare Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-21-068844 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,524,134 Underlying: Common Shares · 250,000 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 22:49 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionCommon Shares | 250,000 | $0.19 | $47,500.00 |
DisclosureSEC source: 0001209191-21-068844 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,589,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Feb 4, 2022 00:00 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
GiftCommon Shares | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006972 · doc5.xml · nonDerivative · entry 2 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,333 F2 · shares: This transaction represents a charitable donation of 250,000 common shares the reporting person donated on December 8, 2021. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 23:01 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
GrantShare Option · Derivative | 406,020 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068851 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,930,154 Underlying: Common Shares · 406,020 shares Expires 2031-12-07 F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 23:00 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
GrantShare Option (right to buy) · Derivative | 920,312 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068850 · doc4.xml · derivative · entry 4 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,913,122 Underlying: Common Shares · 920,312 shares Expires 2031-12-07 F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:58 UTC |
Booth AndrewChief Financial Officer
|
GrantShare Option (right to buy) · Derivative | 406,020 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068849 · doc4.xml · derivative · entry 3 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,884,820 Underlying: Common Shares · 406,020 shares Expires 2031-12-07 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:55 UTC |
Stimart TrynChief Legal Officer
|
GrantShare Option (right to buy) · Derivative | 270,680 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068847 · doc4.xml · derivative · entry 3 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,311,480 Underlying: Common Shares · 270,680 shares Expires 2031-12-07 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 18:13 UTC |
Hayden Michael RDirector
|
GrantShare option (right to buy) · Derivative | 45,532 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068955 · doc4.xml · derivative · entry 4 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,814 Underlying: Common Shares · 45,532 shares Expires 2031-12-07 Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 18:15 UTC |
Montalbano John S.Director
|
GrantShare option (right to buy) · Derivative | 45,532 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068956 · doc4.xml · derivative · entry 4 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,814 Underlying: Common Shares · 45,532 shares Expires 2031-12-07 Read SEC document |
| December 07, 2021 Filed Feb 3, 2022 23:58 UTC |
Thermopylae Holdings Ltd.10% owner
|
GiftCommon Shares | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006967 · doc5.xml · nonDerivative · entry 2 Thermopylae Holdings Ltd. · CIK 0001834449 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,807,290 F2 · shares: This transaction represents a charitable donation of 750,000 common shares the reporting person donated on December 7, 2021. Read SEC document |
| December 07, 2021 Filed Feb 3, 2022 23:56 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
GiftCommon Shares | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006963 · doc5.xml · nonDerivative · entry 3 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 53,807,290 F6 · shares: This transaction represents a charitable donation of 750,000 common shares donated by Thermopylae Holdings Ltd. on December 7, 2021. F5 · ownership.nature: These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the reporting person. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 20:17 UTC |
Lo AndrewDirector
|
PurchaseShare Option (right to buy) | 86,938 | $14.02 | $1,218,870.76 |
DisclosureSEC source: 0001209191-21-068291 · doc4.xml · nonDerivative · entry 1 Lo Andrew · CIK 0001679076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,938 Read SEC document |
| December 03, 2021 Filed Dec 10, 2021 19:36 UTC Amendment |
Lo AndrewDirector
|
GrantShare Option (right to buy) · Derivative | 91,325 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-21-068976 · doc4a.xml · derivative · entry 1 Lo Andrew · CIK 0001679076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,325 Underlying: Common Shares · 91,325 shares Expires 2031-12-03 F1 · shares: The original option award was listed as 86,938 which is an administrative error due to an incorrect the Black-Scholes calculation. The correct number of awarded options is 91,325. F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on December 3, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 19:16 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionShare Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-21-067491 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,774,134 Underlying: Common Shares · 83,333 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 19:16 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionCommon Shares | 83,333 | $14.96 | $1,246,661.68 |
DisclosureSEC source: 0001209191-21-067491 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 3, 2021 22:47 UTC Amendment |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionShare Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-21-067941 · doc4a.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,774,134 Underlying: Common Shares · 83,333 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 30, 2021 Filed Dec 3, 2021 22:47 UTC Amendment |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionCommon Shares | 83,333 | $0.19 | $15,833.27 |
DisclosureSEC source: 0001209191-21-067941 · doc4a.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The original price was listed as $14.96 which is an administrative error. The correct price is $0.19. Read SEC document |
| November 30, 2021 Filed Feb 4, 2022 00:00 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
GiftCommon Shares | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006972 · doc5.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,333 F1 · shares: This transaction represents a charitable donation of 83,333 common shares the reporting person donated on November 30, 2021. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:03 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
Exercise / conversionShare option (right to buy) · Derivative | 224,500 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-21-066133 · doc4.xml · derivative · entry 4 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,992,810 Underlying: Common Shares · 224,500 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:03 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
Exercise / conversionCommon Shares | 224,500 | $15.03 | $3,374,235.00 |
DisclosureSEC source: 0001209191-21-066133 · doc4.xml · nonDerivative · entry 1 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 11:05 UTC |
Booth AndrewChief Financial Officer
|
PurchaseCommon Shares | 14,000 | $14.61 | $204,540.00 |
DisclosureSEC source: 0001209191-21-064378 · doc4.xml · nonDerivative · entry 2 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 130,959 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.67 and $14.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 11:05 UTC |
Booth AndrewChief Financial Officer
|
PurchaseCommon Shares | 53,500 | $14.74 | $788,590.00 |
DisclosureSEC source: 0001209191-21-064378 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,500 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.60 and $14.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 11:05 UTC |
Thermopylae Holdings Ltd.10% owner
|
PurchaseCommon Shares | 202,960 | $14.76 | $2,995,912.86 |
DisclosureSEC source: 0001209191-21-064377 · doc4.xml · nonDerivative · entry 1 Thermopylae Holdings Ltd. · CIK 0001834449 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,807,290 F1 · shares: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $15.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:12 UTC |
Hayden Michael RDirector
|
Exercise / conversionShare option (right to buy) · Derivative | 270,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001209191-21-056163 · doc4.xml · derivative · entry 3 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 270,000 Underlying: Common Shares · 270,000 shares Expires 2029-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.32:USD $1.00 for September 11, 2019 as set forth on Bloomberg. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on September 11, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. F1 · balance_after: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:12 UTC |
Hayden Michael RDirector
|
Exercise / conversionCommon Shares | 270,000 | $17.73 | $4,787,100.00 |
DisclosureSEC source: 0001209191-21-056163 · doc4.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,273,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 18:12 UTC |
HAMER JOHNDirector
|
SaleCommon Shares | 137,351 | $16.93 | $2,325,352.43 |
DisclosureSEC source: 0001209191-21-054543 · doc4.xml · nonDerivative · entry 2 HAMER JOHN · CIK 0001198174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,862 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.56 and $17.38. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: Effective August 20, 2021, DCVC Bio GP, LLC ("DCVC Bio GP"), distributed 428,862 common shares of the Issuer to John Hamer in connection with a pro-rata distribution for no consideration to the members of DCVC Bio GP. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:18 UTC |
Falconer EsterChief Technology Officer
|
Exercise / conversionShare option (right to buy) · Derivative | 875,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-21-054749 · doc4.xml · derivative · entry 2 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Shares · 875,000 shares Expires 2029-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on January 1, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:18 UTC |
Falconer EsterChief Technology Officer
|
Exercise / conversionCommon Shares | 875,000 | $16.89 | $14,778,750.00 |
DisclosureSEC source: 0001209191-21-054749 · doc4.xml · nonDerivative · entry 1 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 18:12 UTC |
HAMER JOHNDirector
|
SaleCommon Shares | 162,649 | $16.95 | $2,756,900.55 |
DisclosureSEC source: 0001209191-21-054543 · doc4.xml · nonDerivative · entry 1 HAMER JOHN · CIK 0001198174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,213 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.64 and $17.51. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: Effective August 20, 2021, DCVC Bio GP, LLC ("DCVC Bio GP"), distributed 428,862 common shares of the Issuer to John Hamer in connection with a pro-rata distribution for no consideration to the members of DCVC Bio GP. Read SEC document |
| August 27, 2021 Filed Dec 10, 2021 18:13 UTC |
Hayden Michael RDirector
|
GrantShare option (right to buy) · Derivative | 34,282 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001209191-21-068955 · doc4.xml · derivative · entry 3 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,282 Underlying: Common Shares · 34,282 shares Expires 2031-08-27 Read SEC document |
| August 27, 2021 Filed Dec 10, 2021 18:15 UTC |
Montalbano John S.Director
|
GrantShare option (right to buy) · Derivative | 34,282 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001209191-21-068956 · doc4.xml · derivative · entry 3 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,282 Underlying: Common Shares · 34,282 shares Expires 2031-08-27 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 21:47 UTC |
Montalbano John S.Director
|
PurchaseCommon Shares | 6,000 | $17.23 | $103,380.00 |
DisclosureSEC source: 0001209191-21-051985 · doc4.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Read SEC document |
| June 22, 2021 Filed Jun 22, 2021 22:50 UTC |
Hayden Michael RDirector
|
SaleCommon Shares | 100,000 | $25.50 | $2,550,000.00 |
DisclosureSEC source: 0000899243-21-025366 · doc4.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,003,397 F1 · kind: On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · shares: On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F2 · ownership.nature: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 18:39 UTC |
HAMER JOHNDirector · 10% owner
|
OtherCommon Shares | 73,892 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025357 · doc4.xml · nonDerivative · entry 2 HAMER JOHN · CIK 0001198174 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 73,892 F1 · kind: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: These securities are held by DCVC Bio GP. JNK and ZNM are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio GP. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio GP. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 18:39 UTC |
HAMER JOHNDirector · 10% owner
|
OtherCommon Shares | 5,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025357 · doc4.xml · nonDerivative · entry 1 HAMER JOHN · CIK 0001198174 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,105,761 F1 · kind: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:13 UTC |
DCVC Bio, L.P.10% owner
DCVC Bio GP, LLC10% owner
JNK Capital Management, LLC10% owner
ZNM Capital Management, LLC10% owner
Bogue Zachary10% owner
Ocko Matthew10% owner
Stead Kiersten10% owner
|
OtherCommon Shares | 73,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042496 · doc4.xml · nonDerivative · entry 2 DCVC Bio, L.P. · CIK 0001735069 · 10% owner DCVC Bio GP, LLC · CIK 0001735070 · 10% owner JNK Capital Management, LLC · CIK 0001836273 · 10% owner ZNM Capital Management, LLC · CIK 0001836103 · 10% owner Bogue Zachary · CIK 0001836157 · 10% owner Ocko Matthew · CIK 0001836089 · 10% owner Stead Kiersten · CIK 0001836117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 73,892 F1 · kind: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: These securities are held by DCVC Bio GP. JNK and ZNM are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio GP. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio GP. F5 · ownership.nature: (Continued from Footnote 4) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:13 UTC |
DCVC Bio, L.P.10% owner
DCVC Bio GP, LLC10% owner
JNK Capital Management, LLC10% owner
ZNM Capital Management, LLC10% owner
Bogue Zachary10% owner
Ocko Matthew10% owner
Stead Kiersten10% owner
|
OtherCommon Shares | 5,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042496 · doc4.xml · nonDerivative · entry 1 DCVC Bio, L.P. · CIK 0001735069 · 10% owner DCVC Bio GP, LLC · CIK 0001735070 · 10% owner JNK Capital Management, LLC · CIK 0001836273 · 10% owner ZNM Capital Management, LLC · CIK 0001836103 · 10% owner Bogue Zachary · CIK 0001836157 · 10% owner Ocko Matthew · CIK 0001836089 · 10% owner Stead Kiersten · CIK 0001836117 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,105,761 F1 · kind: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio. F3 · ownership.nature: (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:00 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionShare Option (right to buy) · Derivative | 333,333 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0000899243-21-024295 · doc4.xml · derivative · entry 5 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,667 Underlying: Common Shares · 333,333 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on November 8, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. F5 · derivative.expiration_date: Expiration date corrected from the date listed on the Form 3 filed on December 11, 2020. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 00:00 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
Exercise / conversionCommon Shares | 333,333 | $0.19 | $63,333.27 |
DisclosureSEC source: 0000899243-21-024295 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:14 UTC |
Thermopylae Holdings Ltd.10% owner
|
SaleCommon Shares | 5,598,420 | $24.03 | $134,530,032.60 |
DisclosureSEC source: 0000899243-21-022994 · doc4.xml · nonDerivative · entry 1 Thermopylae Holdings Ltd. · CIK 0001834449 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,604,330 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:11 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
SaleCommon Shares | 401,580 | $25.50 | $10,240,290.00 |
DisclosureSEC source: 0000899243-21-022993 · doc4.xml · nonDerivative · entry 2 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 233,500 F3 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F3 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F3 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F4 · ownership.nature: These shares are held by Hankla Family Trust (2019), of which the Reporting Person and his spouse are joint trustees. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:11 UTC |
Hansen Carl L. G.Director · Chief Executive Officer · 10% owner
|
SaleCommon Shares | 5,598,420 | $24.03 | $134,530,032.60 |
DisclosureSEC source: 0000899243-21-022993 · doc4.xml · nonDerivative · entry 1 Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 55,604,330 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03. F2 · ownership.nature: These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the Reporting Person. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:01 UTC |
Lecault VeroniqueDirector · Chief Operating Officer
|
SaleCommon Shares | 1,000,000 | $25.50 | $25,500,000.00 |
DisclosureSEC source: 0000899243-21-022990 · doc4.xml · nonDerivative · entry 1 Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 273,630 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F2 · kind: The sale of the shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), to the extent of 23,000 shares, with the purchase by the Reporting Person of 6,000 shares at a price of $20 per share on December 15, 2020, and the purchase by the Reporting Person's spouse of 17,000 shares at a price of $20 per share on December 15, 2020, as reported previously on the Reporting Person's Form 4 filed on December 17, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F3 · ownership.nature: These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:01 UTC |
Stimart TrynChief Legal Officer
|
SaleCommon Shares | 1,000,000 | $25.50 | $25,500,000.00 |
DisclosureSEC source: 0000899243-21-022989 · doc4.xml · nonDerivative · entry 1 Stimart Tryn · CIK 0001834424 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F2 · kind: The sale of the shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), to the extent of 500 Shares, with the purchase by the Reporting Person of 250 Shares at a price of $20 per share on December 15, 2020, and the purchase by the Reporting Person's spouse of 250 Shares at a price of $20 per share on December 15, 2020, as reported previously on the Reporting Person's Form 4 filed on December 17, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:00 UTC |
Falconer EsterChief Technology Officer
|
SaleCommon Shares | 1,000,000 | $25.50 | $25,500,000.00 |
DisclosureSEC source: 0000899243-21-022987 · doc4.xml · nonDerivative · entry 1 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:00 UTC |
Booth AndrewChief Financial Officer
|
SaleCommon Shares | 1,200,000 | $25.50 | $30,600,000.00 |
DisclosureSEC source: 0000899243-21-022988 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.